H.C. Wainwright Reiterates Buy Rating on Gyre Therapeutics (GYRE) following acquisition announcement Mar 2, 2026 11:58AM
Gyre Therapeutics receives CDE alignment on conditional approval pathway for Hydronidone Jan 5, 2026 07:13AM
Gyre Therapeutics (GYRE) Misses Q3 EPS by 2c Nov 7, 2025 04:13PM
H.C. Wainwright Reiterates Buy Rating on Gyre Therapeutics (GYRE) Oct 16, 2025 06:43AM
Jefferies Starts Gyre Therapeutics (GYRE) at Buy Oct 10, 2025 05:04AM


Aug 26, 2025 07:10AM H.C. Wainwright Starts Gyre Therapeutics (GYRE) at Buy
Aug 11, 2025 04:46PM Gyre Therapeutics (GYRE) Misses Q2 EPS by 2c
Jun 10, 2025 07:07AM Gyre Therapeutics (GYRE) Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
May 23, 2025 05:53AM Gyre Therapeutics (GYRE) Offering 2.2M Shares at $9 Per
May 22, 2025 04:03PM Gyre Therapeutics (GYRE) announces Hydronidone met endpoint in Phase 3 trial
May 22, 2025 04:03PM Gyre Therapeutics (GYRE) Announces Proposed Underwritten Public Offering of Common Stock
May 9, 2025 04:48PM Gyre Therapeutics (GYRE) Misses Q1 EPS by 3c
Mar 31, 2025 07:02AM Gyre Therapeutics (GYRE) Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
Mar 27, 2025 07:00AM Gyre Therapeutics (GYRE) Announces Publication of Protocol for Phase 3 Trial Evaluating F351
Mar 17, 2025 05:26PM Gyre Therapeutics (GYRE) Reports In-Line Q4 EPS
Jan 6, 2025 07:01AM Gyre Therapeutics (GYRE) Appoints Ping Zhang to its Board
Nov 14, 2024 04:49PM Gyre Therapeutics (GYRE) Files Mixed Shelf
Nov 13, 2024 05:07PM Gyre Therapeutics, Inc. (GYRE) Reports Q3 EPS of $0.01
Aug 13, 2024 07:22AM Gyre Therapeutics, Inc. (GYRE) Reports Q2 EPS of $0.01
Aug 8, 2024 04:09PM Gyre Therapeutics (GYRE) Appoints David M. Epstein to its Board
Jul 2, 2024 04:06PM Gyre Therapeutics (GYRE) Announces China’s NMPA Approval of Avatrombopag Maleate Tablets